GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haw Par Corp Ltd (OTCPK:HAWPF) » Definitions » EV-to-EBIT

Haw Par (Haw Par) EV-to-EBIT : -4.21 (As of Apr. 25, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Haw Par EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Haw Par's Enterprise Value is $-726.8 Mil. Haw Par's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $172.5 Mil. Therefore, Haw Par's EV-to-EBIT for today is -4.21.

The historical rank and industry rank for Haw Par's EV-to-EBIT or its related term are showing as below:

HAWPF' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.7   Med: 0.06   Max: 11.64
Current: -4.46

During the past 13 years, the highest EV-to-EBIT of Haw Par was 11.64. The lowest was -9.70. And the median was 0.06.

HAWPF's EV-to-EBIT is ranked better than
99.4% of 670 companies
in the Drug Manufacturers industry
Industry Median: 17.115 vs HAWPF: -4.46

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Haw Par's Enterprise Value for the quarter that ended in Dec. 2023 was $-748.0 Mil. Haw Par's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $172.5 Mil. Haw Par's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -23.06%.


Haw Par EV-to-EBIT Historical Data

The historical data trend for Haw Par's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haw Par EV-to-EBIT Chart

Haw Par Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.27 -3.34 -5.26 -6.45 -4.43

Haw Par Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.26 - -6.45 - -4.43

Competitive Comparison of Haw Par's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Haw Par's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haw Par's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haw Par's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Haw Par's EV-to-EBIT falls into.



Haw Par EV-to-EBIT Calculation

Haw Par's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-726.813/172.493
=-4.21

Haw Par's current Enterprise Value is $-726.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haw Par's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $172.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haw Par  (OTCPK:HAWPF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Haw Par's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=172.493/-748.02512
=-23.06 %

Haw Par's Enterprise Value for the quarter that ended in Dec. 2023 was $-748.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haw Par's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $172.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haw Par EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Haw Par's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Haw Par (Haw Par) Business Description

Traded in Other Exchanges
Address
401 Commonwealth Drive, No. 03-03 Haw Par Technocentre, Singapore, SGP, 149598
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates a majority of its revenue from the ASEAN countries.

Haw Par (Haw Par) Headlines

From GuruFocus

Haw Par Stock Is Believed To Be Significantly Overvalued

By GF Value GF Value 03-31-2021

First Eagle Comments on Haw Par

By Holly LaFon Holly LaFon 04-24-2018

Singapore Based Haw Par Selling at a Discount to NAV

By Holmes Osborne, CFA Holmes Osborne, CFA 07-26-2016